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Abstract
Metastasis accounts for almost 90% of cancer-associated mortality. The effectiveness of cancer 
therapeutics is limited by the protective microenvironment of the metastatic niche and 
consequently these disseminated tumors remain incurable. Metastatic disease progression 
continues to be poorly understood due to the lack of appropriate model systems. To address this 
gap in understanding, we propose an all-human microphysiological system that facilitates the 
investigation of cancer behavior in the liver metastatic niche. This existing LiverChip is a 3D-
system modeling the hepatic niche; it incorporates a full complement of human parenchymal and 
non-parenchymal cells and effectively recapitulates micrometastases. Moreover, this system 
allows for real-time monitoring of micrometastasis and assessment of human-specific signaling. It 
is being utilized to further our understanding of the efficacy of chemotherapeutics by examining 
the activity of established and novel agents on micrometastases under conditions replicating 
diurnal variations in hormones, nutrients and mild inflammatory states using programmable 
microdispensers. These inputs affect the cues that govern tumor cell responses. Three critical 
signaling groups are targeted: the glucose/insulin responses, the stress hormone cortisol and the 
gut microbiome in relation to inflammatory cues. Currently, the system sustains functioning 
hepatocytes for a minimum of 15 days; confirmed by monitoring hepatic function (urea, α-1-
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antitrypsin, fibrinogen, and cytochrome P450) and injury (AST and ALT). Breast cancer cell lines 
effectively integrate into the hepatic niche without detectable disruption to tissue and preliminary 
evidence suggests growth attenuation amongst a subpopulation of breast cancer cells. xMAP 
technology combined with systems biology modeling are also employed to evaluate cellular 
crosstalk and illustrate communication networks in the early microenvironment of 
micrometastases. This model is anticipated to identify new therapeutic strategies for metastasis by 
elucidating the paracrine effects between the hepatic and metastatic cells, while concurrently 
evaluating agent efficacy for metastasis, metabolism and tolerability.
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INTRODUCTION
Metastasis is the leading cause of cancer-associated mortality. The development of 
metastases involves a series of sequential biological processes that allow the spread of 
cancer cells from a primary site to secondary organs. Cells escape from the primary tumor 
by intravasating into the circulation followed by extravasation into the parenchyma of a 
distant organ (1). Those cells that successfully disseminate may either outgrow immediately 
or lay dormant, as small or pre-malignant micrometastases, for years to decades before 
becoming clinically evident (2, 3). This is especially daunting in the case of breast cancer 
where even though the primary tumor is often successfully treated, up to 30% of women 
with early stage breast cancer will eventually relapse with metastatic disease (4). Due to the 
widespread distribution of metastatic tumors and the protective effects of the metastatic 
microenvironment, the effectiveness of cancer therapeutics is limited and consequently 
recurrent cancers remain largely incurable.
One of the major hurdles impeding the development of cancer therapeutics to target 
micrometastases is the limitations of current model systems. Animal models are not suitable 
for this type of study as they generally only provide endpoint analyses in addition to issues 
of relevance for the human condition (5, 6). Typically, immunocompromised murine models 
are used (7–9), yet studies have demonstrated that immune systems are crucial to the 
micrometastatic microenvironment (10, 11). Those animal studies that do use syngeneic 
models are not fully representative of the human situation due to interspecies differences in 
cytokines and metabolism (6). While in vitro culture investigations can avoid the cross 
species issues, the current 2D culture systems lack important aspects which impact tumor 
behavior, such as 3D architecture to provide tissue depth for tumor intercalation; functional 
aspects, including fluid flow and control of oxygen content, and do not allow for extended 
culture. There is also a distinct absence of models capable of recreating micrometastasis 
while concurrently providing for the evaluation of agent efficacy, toxicity and metabolism. 
For these reasons, a number of investigators have utilized organotypic cultures in bioreactors 
as investigative tools to overcome such issues (12–17).
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THE LIVER AS THE METASTATIC TARGET
The liver represents an ideal organ system to study both micrometastasis and the efficacy of 
cancer therapeutics. Firstly, it is a major site of metastasis for a wide range of carcinomas 
(e.g. breast, lung, colon, prostate, brain, melanomas). Depending on the primary tumor type, 
30–70% of patients dying from cancer have hepatic metastases (18). Secondly, the liver is 
the major site for drug metabolism (both activation and detoxification), a significant factor 
in determining efficacy and limiting toxicities of cancer therapies (19). Further, there is 
evidence that metastatic disease alters liver function, potentially increasing toxicity, as well 
as changing efficacy of the agent upon the tumor (20).
The liver architecture is suited for its diverse functions such as metabolism, detoxification, 
and regulation of multifaceted defense mechanisms. It is composed of a complex assembly 
of highly specialized parenchymal and non-parenchymal cell types (Figure 1). The 
parenchymal hepatocytes are responsible for most metabolic functions along with the 
production of the majority of the circulating plasma proteins, transporters, protease 
inhibitors, blood coagulation factors and immune modulators. The non-parenchymal cellular 
portion represents 20 – 40% of the liver and is primarily comprised of liver sinusoidal 
endothelial, Kupffer and stellate cells. The non-parenchymal cells are essential components, 
releasing substances under both normal and pathological conditions that regulate many 
hepatocyte functions (21).
As mentioned above, the liver is a major site for drug metabolism. The metabolic processes 
generally involve converting drugs into more hydrophilic compounds in order for them to be 
excreted in the bodily fluids (e.g. urine or bile). The cytochrome P450 family of enzymes is 
primarily responsible for the metabolism of several essential chemotherapy agents. There 
are more than 50 cytochrome P450 enzymes with approximately 90% of drugs metabolized 
through CYP3A4/5, CYP2C9, CYP2C19, CYP2D6 and CYP1A2 (22). In particular, the 
CYP3A subfamily has been identified to play a predominant role in metabolizing 
chemotherapeutics (23, 24).
The liver is also one of the primary sites of systemic regulation of circadian rhythms via 
modulations of hormones, nutrients and inflammatory cytokines. Cell proliferation and 
metabolic rhythms are regulated by circadian cycles, and often show asynchronies between 
normal and malignant tissues (25). It is currently unknown how the molecular signals that 
change on a diurnal basis at both the systemic and local level influence the complex 
micrometastatic microenvironment. However, these circadian rhythms are known to alter the 
metabolic capabilities of the liver at the transcription, protein, and enzymatic levels (26). It 
is reasonable to expect that such rhythms would alter micrometastases and/or how 
chemotherapeutic agents are handled.
LIVERCHIP MICROPHYSIOLOGICAL MODEL
A major challenge in the field of hepatic tissue engineering is the development of ex vivo 
and in vitro hepatic tissues that both exhibit a stable phenotype and maintain liver 
parenchymal function. Further, investigating metastatic seeding and survival of cells 
requires examination over a period of days-to-weeks. Numerous 2D and 3D in vitro liver-
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based systems have been developed and are extensively reviewed (27). Extended evaluation, 
required for metastasis research, is not recreated in conventional 2D cultures which 
generally only remain viable and functional for <7 days (28); the addition of a second layer 
of collagen for a ‘sandwich’ can extend hepatocyte functioning for longer in select settings 
(28a, 29). Additionally, dedifferentiation of hepatocytes in these standard 2D culture is well 
established which subsequently causes a reduction in liver functions (e.g. downregulation of 
enzymes and reduced production of plasma proteins such as albumin) (30–34). Numerous 
developments in recent years, notably microfluidics and cell positioning techniques, have 
overcome some of the aforementioned disadvantages of conventional 2D cultures, primarily 
by controlling metabolite accumulation and non-steady-state conditions allowing for 
extended culturing (35–37).
For our investigations and as a possible approach going forward, we utilize an all-human 
LiverChip microphysiological 3D system (Zyoxel, Ltd; Oxford, UK) that faithfully models 
both the hepatic niche and micrometastatic tumor cells (34). The liver bioreactor employed 
by our laboratory has already provided insight into the phenotypic plasticity of both breast 
and prostate carcinoma cells (38–41). Notably, the bioreactor milieu provides for a greater 
chemoresistance that cannot be extrapolated from 2D studies (42). We continue to develop 
and improve this system as detailed below. A more detailed overview of the technical 
aspects of the LiverChip system and the bioengineering behind the model is described in 
Wheeler et al., (43).
Functional hepatic niche
We aimed to replicate the fundamental physiologic functions and conditions of the hepatic 
niche, including multi-cellular composition, metabolism, protein production, and circadian 
cycles (Figure 2 and 3A and B). The LiverChip bioreactor successfully recreates and 
maintains all-human hepatic tissues with structural integrity and functional complexity for 
weeks in culture. It also provides adequate samples for multiple downstream assays while 
avoiding materials that adsorb steroid hormones and drugs. The system incorporates fresh 
human hepatocytes and a full complement of non-parenchymal cells, at physiologically 
relevant ratios. Cultures are maintained for a minimum of 15 days in defined, serum-free 
medium that supports cell differentiation in culture and can be modified to reflect circadian 
changes (i.e., insulin, glucagon, glucose and cortisol). The human hepatocytes and non-
parenchymal cells are sourced mainly from therapeutic partial hepatectomies for metastatic 
colorectal carcinoma or other benign diseases such as focal nodular hyperplasia. Many of 
the tissue isolations are consequently from patients who previously had chemotherapy for 
colorectal liver metastases. However, prior work has demonstrated that the viability and 
function of hepatocytes previously exposed to such agents remains unaltered (44).
A thorough characterization of isolated hepatocytes is essential to ensure that functionality is 
sustained during culture. The investigation of morphology in combination with protein 
secretion, predominantly albumin, is frequently used as verification of hepatocyte 
functionality. However, these parameters alone do not necessarily correlate with the 
existence of other hepatocyte-specific functions (45, 46). Subsequently, a high level of 
importance and attention has been placed upon ensuring the health and functionality of the 
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hepatic tissue in the LiverChip, and as such a comprehensive set of biomarkers has been 
developed (Figure 2). A key measurement of functionality for our system is active 
cytochrome P450 metabolism. Previously, we have developed and validated an assay 
method to simultaneously evaluate the activity of 5 different cytochrome P450 enzymes 
with the rate of metabolism extrapolated as picomoles of substrate metabolized or 
metabolite formed per minute per million cells (47). Functionality is further assessed 
through determining levels of glucose consumption/production, urea catabolism as well as 
the secretion of positive acute phase proteins, such as alpha-1-antitrypsin (A1AT) and 
fibrinogen. Maintained health is verified via the production of aspartate transaminase (AST) 
and alanine aminotransferase (ALT), intracellular proteins released from hepatocytes during 
times of injury and are monitored clinically. Importantly, all these measurements can be 
monitored in real-time over the course of an experiment. A variety of imaging modalities are 
also employed for additional confirmation of hepatocyte health and functionality, including 
confocal or multiphoton assessment of post-immunolabeled reactors for viability (e.g. 
calcein AM/ethidium bromide, albumin), maintained presence of non-parenchymal 
components (e.g. CD45, Lyve-1, CD68, desmin), cell-cell interactions (e.g. E-cadherin, F-
actin, α-smooth muscled actin) etc. Each reactor scaffold can be uniquely processed to 
collect a wide variety of visual information. Some initial data pertaining to these assays is 
presented in Figure 3B (I, ii and iii).
The LiverChip system is continually being assessed for ways to bring it closer to 
recapitulating an in vivo liver. Although the system allows for the generation of sufficient 
effluent samples for the plethora of downstream assays described above, this comes with the 
limitation of requiring a considerable number of cells per well. Further, while functionality 
is successfully achieved, we have not yet recapitulated liver structure within the present 
scaffolding matrices. The scaffolds are of a rigid nature which is associated with non-
specific inflammatory responses in tissues (48). Investigations are currently underway which 
are perusing new functionalized matrices and scaffolding that more accurately reflect the 
rheology of the liver as well as aid in recreating liver architecture in vitro.
Recapitulating micrometastasis
In order to develop rational approaches to target growing cancer cells and promote clinically 
undetectable micrometastases towards a dormant state, integrated in vitro systems are 
needed that can support the initial micrometastatic nodules and follow such nodules for 
extended periods in culture.
The LiverChip, and other simular moderate-throughput organotypic systems offer the ability 
to evaluate the role of the the diversity of the human population in the micrometastatic 
tumor microenvironment in an all-human system in which the liver environment comes from 
individual patients. We have previously characterized other bioreactor systems to examine 
the metastatic behaviors of breast and prostate cancer cells (38–41). These 
microphysiological systems not only effectively recapitulate metastasis but also concurrently 
allows for real-time monitoring of metastasis and assessment of human-specific signaling. 
Moreover, the system is evaluable over weeks, having been tested through 30 days, with 
computer programmable inputs or delivery of modifiers (e.g. hormones, proteins, 
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metabolites, inhibitors) that allow one to define specific required signals that either promote 
or hinder specific metastatic properties (43). The main breast cancer cell lines utilized are 
the well-characterized metastatic MDA-MB-231 and non-aggressive MCF-7 breast 
carcinoma cell lines. In order to track and monitor tumor burden within the hepatic niche, 
the cells lines have been modified to express fluorescent labels.
Upon seeding individual carcinoma cells (the number per well determined by cell 
concentration and number introduced into each unit) into engineered hepatic tissue, 
individual cells survive, form nodules, and can grow into mm-size tumor masses under the 
constant perfusion flow. A tissue is generated that comprises a hybrid of unaffected host 
tissue and tumor boundary, which is representative of the histological distinctions observed 
in human tumors (40, 42). Importantly, the breast cancer cell lines, MDA-MB-231 and 
MCF-7, successfully integrate into and alongside the hepatic niche without detectable 
disruption to tissue. Markers of health (AST, ALT) and function (cytochrome P450 activity, 
glucose consumption, urea catabolism, acute phase protein production) remain at levels 
comparable to that of unburdened hepatic tissue (unpublished data). Furthermore, 
preliminary evidence suggests growth attenuation amongst a subpopulation of the highly 
proliferative and invasive MDA-MB-231 cell line when these cells intercalate as individual 
cells within the tissue parenchyma (unpublished data).
Previous work also demonstrates that in the context of the 3D liver microbioreactor, breast 
carcinoma cells undergo a phenotypic shift to a more epithelioid phenotype with intimate 
connections to the hepatic cells (40, 42). This was noted not just with human cell lines, but 
also with primary explants from breast, prostate and melanoma (42). This phenotype is often 
noted in small metastatic nodules of patients, wherein the metastases appear more 
differentiated than the primary tumor (39, 49–52). Furthermore, the reversion to a more 
epithelioid phenotype in the MDA-MB-231 was associated with enhanced chemoresistance. 
This was observed though reduced cell death by chemotherapies in MDA-MB-231 cells 
over-expressing E-cadherin compared to E-cadherin negative MDA-MB-231 and MDA-
MB-231-shEcad cells; this protection from death was abrogated by an E-cadherin antibody. 
Conversely, driving the epithelial MCF-7 cells towards a proliferative mesenchymal 
phenotype increased their sensitivity (42). The greater chemoresistance conferred by re-
expression of E-cadherin mimics the resistance noted in patients (39). The extent of 
resistance (as determined by LD50) is orders of magnitude greater for tumors grown in the 
3D liver system (unpublished data) compared to those grown in 2D cultures either with 
hepatocytes or with forced E-cadherin expression alone (42). This difference in 
chemotherapeutic efficacy between 3D and 2D models is well established within the 
literature (53–55). Many critical signals, regulators and the micrometastatic architecture are 
not present when cells are cultured under standard 2D conditions (56). The cellular 
architecture and growth conditions recreated by 3D cultures more accurately mimics the in 
vivo behavior of metastatic cancer cells and is key for accurate prediction of drug efficacy 
during the discovery process.
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EVALUATION AND DEVELOPMENT OF CANCER THERAPIES
The most challenging step in the development of therapies for metastasis relates to treating 
the small and pre-malignant micrometastases. Therapies are required which are either 
directly toxic towards the proliferating metastatic cells or lock the clinically irrelevant 
micrometastases in their dormant state. The different biology of the metastatic site requires 
an understanding as to how the efficacy and toxicity of chemotherapy is linked in the 
metastatic niche. This niche is affected directly by the molecular signals and cellular 
behaviors of the cancer cells themselves as well as the surrounding microenvironment, 
which is also altered based upon circadian fluctuations of metabolites and inflammatory 
mediators.
A fundamental element important to the investigating the efficacy of chemotherapies is the 
simple fact that the levels of hormones, nutrients and immune regulators are not static in 
nature, they fluctuate based the circadian cycles. Going forward, we therefore ask if 
circadian fluctuations that modulate metabolism and hormones also influence the efficacy 
and toxicity/detoxification of chemotherapy agents against metastatic tumors. Such 
questions can be analyzed via the LiverChip as it intimately links the efficacy and hepatic 
metabolism of therapeutic agents while concurrently controlling diurnal variations as well as 
mild inflammatory states.
Influence of physiological parameters on metastases and efficacy of chemotherapies
The LiverChip model is being utilized to further our understanding of the efficacy of cancer 
therapeutics towards these micrometastases by examining the activity of established and 
novel agents under conditions replicating circadian variations in key components of the 
portal circulation (nutrients, insulin), the systemic circulation (cortisol) and mild 
inflammatory states using programmable microdispensors (43). Three critical physiologic 
parameters are assessed: the glucose/insulin responses, the stress hormone cortisol and the 
gut microbiome in relation to inflammatory cues. We aim to capture unique insights into the 
responses of the tumor and parenchymal cells to the complexity of key circadian/diurnal 
cycles of hormones and other signals.
Impact of physiological diurnal fluctuations in the microenvironment—
Investigations into the mechanisms by which the circadian fluctuations affect tumor cell 
proliferation as well as the parenchymal functions of the liver may lead to innovative 
therapeutic targets or regimes. Chronotherapy, the administration of drugs at a certain time 
of day, has already shown promise in treating cancer with evidence to suggest that there may 
be a window of time when a cytotoxic drug could kill the malignant cells more effectively 
than the normal host cells (26). Importantly, the peak time for the chronomodulated delivery 
of chemotherapy has been shown to determine the tolerability of patients with metastatic 
disease (57). There is also accumulating epidemiological data indicating that disruption of 
circadian rhythms promotes tumorigenesis and progression (25). Recent work has indicated 
that, contrary to existing dogma, fasting may be more efficacious in chemotherapy 
treatments by protecting healthy cells at high doses of chemotherapy (58). However, 
whether chronobiological dosing will be more effective in treating micrometastases is 
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unknown, due to our inability to probe responses of these small tumors in the clinical 
setting. A large gap exists in linking the complex metastatic microenvironment to molecular 
signals that change on a diurnal basis at both the systemic and local level. We have 
developed and demonstrated a modification to the LiverChip system that integrates onto the 
platform multiplexed microdispensers capable of programmable delivery of compounds with 
high precision, thereby enabling accurate, flexible and programmable diurnal control (Figure 
3C and D). This modified LiverChip model is capable of filling this gap as both phenotypes 
and mechanisms can be investigated.
Diurnal control of nutrients and hormones is anticipated to have a significant impact upon 
both tumor growth characteristics and hepatocyte metabolism. It is likely to give rise to both 
macroscopic and molecular behaviors that are different from those in standard culture. 
Under diurnal conditions, it is anticipated that a more attenuated growth phenotype in the 
tumor cells will be observed. Circadian rhythms also have an important impact on drug 
effectiveness and toxicity as drug metabolism by the liver is regulated by circadian 
influences upon the activity of xenobiotic-metabolizing enzymes (e.g. cytochrome P450) 
(59). Subsequently, the timing of treatment chemotherapeutic agents will be of great 
importance due to the influence of circadian rhythms over efficacy (26). Therefore, diurnal 
control should bring us closer to more effectively recapitulating physiologically relevant 
conditions reflective of the in vivo micrometastatic nodule and subsequently direct a more 
accurate assessment of the efficacy of chemotherapeutic agents.
Presently, the vast majority of standard culture systems conventionally employ medium that 
contains supra-physiological levels of cortisol, insulin and glucose. We anticipate that these 
supra-physiological conditions of standard cultures stimulate uncontrolled metastases 
resulting in easier eradication by chemotherapeutic agents that target proliferation. This then 
causes overestimation of therapeutic efficacy (59a). Therefore, the levels utilized to 
investigate diurnal fluctuations in hormones and nutrients will mimic those in the human 
body.
Impact of mild inflammatory states in the microenvironment—The greatest 
clinical conundrum for all cancers, but particularly for breast carcinoma, is the ability for 
disseminated cells to lie dormant for years before emerging as a relentlessly aggressive 
disease. While the mechanisms currently remain unknown, evidence is emerging that 
inflammatory cytokines and matrix components may play at least a part in driving small and 
pre-malignant micrometastasis into a proliferative state (60–62). These signals can emerge 
from a variety of insults or even physiological situations.
The liver receives blood from the portal circulation that has bacterial inflammatory initiators 
from the gut microbiome, in addition to inflammatory cytokines and chemokines from the 
spleen and Peyer’s patches (21). We look to establish the influence of mild inflammatory 
states on tumor phenotype and chemoresistance. In the assessment of such studies, the 
common portal blood contaminant lipopolysaccharide will serve as the exogenous stimulant. 
Although the liver clearly handles such challenges routinely, higher loads may overwhelm 
the adaptive response and lead to overt inflammation, with activation of the non-
parenchymal cells. The subsequent production of inflammatory cytokines and matrix 
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components by non-parenchymal cells may then drive the cancer cells into a proliferative 
state. Of the non-parenchymal cells, stellate cells have been shown to promote the growth 
and invasion of colon cancer metastases in the liver of mice through the secretion of SDF-1 
(63). Additionally, Kupffer cells secrete an arsenal of cytokines, growth factors and matrix-
degrading enzymes that are known to support extravasation, motility and invasion (64). 
Endothelial cells are known to be important for tumor outgrowth as demonstrated by the 
continuing clinical trials involving angiogenesis inhibitors as targeted therapies (65), and 
have also been associated with promoting immunotolerance by rendering T cells non-
responsive to tumor antigen-specific stimulation (66). Importantly, from a broader 
perspective, immune and stromal cells are well established to play pivotal roles in regulating 
pre-metastatic niches (67)
A second initiator of an inflammatory or stressed milieu is tissue stiffness (29, 68). It has 
been established that a collagen-rich fibrotic microenvironment drives epithelial cells 
towards a mesenchymal phenotype in which the cells can proliferate and migrate 
inappropriately. Chronic inflammation leads to such a situation in the liver in particular, 
wherein there is a feed-forward mechanism by which fibrosis leads to increased pressure in 
the liver sinusoid, which in turn leads to further fibrosis.
This mild inflammatory milieu would also affect the liver functioning, and likely cancer 
chemoresponsiveness through altered agent metabolism. However, given the plethora of cell 
types and signals involved, it is not possible to predict the sensitivity of cancer cells to 
chemotherapy during chronic exposure to mild inflammatory states. In theory, the greater 
proliferative fraction should increase chemoresponsiveness, while the inflammatory milieu 
should promote resistance, making this model crucial in order to elucidate effective avenues 
for metastatic therapies.
Communication network in the early microenvironment of the hepatic niche
The metastatic microenvironment is composed of a complex milieu of external cues arising 
from the tumor, stromal, and parenchymal cells. To reconstitute intercellular communication 
in the early microenvironment of micrometastases, the all-human cellular composition of the 
LiverChip facilitates the investigation of human-specific cellular crosstalk between tumor 
and hepatic tissues. Yet, to model and ultimately predict responses of multiple cell types 
requires the integration of experimental and computational approaches. In recent years, a 
systems biology framework has advanced molecular, cell, and tissue biology towards a more 
predictive capability.
“Data-driven” models have emerged as standard tools for systems-level research of 
signaling networks. With specific applications towards understanding disease 
pathophysiology, data-driven models are employed to elucidate relationships, interactions, 
and influences among multivariate components. These perspectives offer more robust 
insights compared to reductionist studies focused on individual entities. Such models enable 
the integration of data obtained from different metrics assessed at diverse physiological 
scales. Within our experimental system, integration of complex cytokine, acute phase 
protein, phenotypic responses (e.g., death or survival) and metabolic data arising from the 
growth of small micrometastatic nodules is attainable (Figure 4).
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Conceptually, data are assessed by multivariate analyses such as hierarchical clustering, 
principal component analysis (PCA), and partial least squares (PLS, e.g. PLSR and PLSDA) 
by extracting groups of molecular activities that are statistically associated with an 
established cell behavior or phenotype. As a result, insights gleaned from multivariate 
analyses generate new hypotheses, which are then tested by experiments.
Although a systems biology framework continues to revolutionize our understanding of 
disease pathophysiology and accelerate drug discovery efforts (8, 69, 70), we anticipate that 
data-driven models will identify markers in early metastatic disease, as well as during 
evaluations of drug efficacy and toxicity.
CLINICAL IMPLICATIONS
Whilst progress has been made in our understanding and treatment of metastatic disease, it 
currently remains incurable. An advantage of this physiologically representative, all-human 
liver bioreactor is the concurrent assessment of new as well as existing agents against 
micrometastases. Moreover, the base organotypic system was originally developed for and is 
now in use as a consistent and robust drug testing model in which human metabolism of 
agents can be recreated (71). Generally, chemotherapeutic drug testing against cancer cells 
in ex vivo or in vitro settings fail to simultaneously capture agent metabolism as well as the 
contribution of the microenvironment on carcinoma cell responsiveness (e.g. circadian 
variations, tumor-parenchymal interactions, immunological perturbations and fluid flow). 
This LiverChip is capable of recapitulating both critical aspects for human efficacy 
prediction. Additionally, primary breast carcinoma cells as previously described (40, 42) can 
be incorporated into the system to bring us closer to the patient experience. Animals models 
of Patient-Derived Xenografts (PDx) have shown that human tumor grafts transplanted into 
mice can be predictive of patient response to therapy (72). Therefore, once established, this 
system may also be used to assess responses of human patient tumor samples to 
chemotherapies. This would alleviate the need for animal involvement and also serve as an 
excellent screen for ascertaining the most effective personalized treatment regime for 
individuals afflicted with cancer.
SUMMARY
We focus on occult micrometastatic behaviors as these represent substantial challenges in 
preclinical development due to the complexities of identifying these nodules and monitoring 
their response to therapies in the clinical setting. The LiverChip has the unique inherent 
advantage of intimately linking the evaluation of therapeutic efficacy for metastasis with 
metabolism and tolerability. Not only is it a major organ for xenobiotic detoxification, but it 
is also a main site for metastasis. Cancer cells produce many factors and metabolites that 
alter the surrounding tissue, it is likely that metabolism of agents are altered by hepatocyte 
crowding and loss, as well as the signals from tumors (73). These reciprocal paracrine 
effects likely alter both efficacy and toxicity/detoxification. The essential point of linkage 
would be even more labile in the face of cyclical changes in hormones, nutrients and 
inflammatory modulators. Subsequently, investigations of these essential parameters are 
anticipated to yield markers of micrometastatic behavior that will enable better clinical 
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monitoring, and guide the design of clinical studies. Additionally, this metastatic model is 
readily transferable to other organs and cancer type. This system has the potential to be used 
to evaluate the mechanisms leading to and promoting the escape and outgrowth of dormant 
micrometastatses. Additionally, this metastatic model could be readily transferable to other 
organs and cancer types after optimizing microenvironmental conditions.
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Figure 1. Cellular composition of the liver
Highly specialized parenchymal and non-parenchymal cell types populate the liver. The 
hepatocytes form the parenchymal portion, while the non-parenchymal portion comprises 
multiple cellular types, predominantly liver sinusoidal endothelial, Kupffer and stellate cells.
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Figure 2. LiverChip experimental schematic to probe for function and tumor outgrowth
Day 0, the LiverChip system (Zyoxel, Ltd.) is seeded with hepatocytes and non-
parenchymal cells. Day 1, the medium is changed to serum free maintenance medium. Day 
3, the hepatic tissue has formed and is seeded with RFP+ breast cancer cells (MCF-7 or 
MDA-MB-231). Cytochrome P450 activity is assessed on day 3 and 13. Medium was 
changed every 2 days and effluent samples taken routinely. To monitor the influence of 
circadian rhythms, sampling frequency is increased to at least 7 times per day. The hepatic 
niche is maintained for a minimum of 15 days. Assays to assess hepatocyte health and 
function, cytokine profiles as well as tissue morphology and cellular phenotype are 
performed on the tissue and effluent samples.
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Figure 3. The LiverChip microphysiological system
A) Aerial view of the LiverChip plate. Cells are seeded into the scaffold area, fluid flows up 
through this region across the oxygenation channel and is then recirculated via the reservoir. 
B) Functional and healthy hepatic tissue is formed and maintained for 15 days in the 
LiverChip. i – Hepatocyte injury markers, AST and ALT, continue to decrease as tissue 
formation matured in the LiverChip system (n = 2 donors). Following isolation and seeding 
into the system, the levels are high but as the cells establish tissue they drop to near 
undetectable levels. ii, iii – Hepatocytes still produce albumin (day 15) and maintain 
cytochrome P450 activity (day 3 and 13) over the culture period (n= 2 donors). C) An array 
of microdispensers can be mounted over the LiverChip system providing for precise 
delivery of drug, hormone and nutrient boluses as small as 100 nL. D) When used in 
conjunction with custom-made software and electronic controllers, programmable diurnal 
control of drug concentrations within the bioreactor can be achieved.
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Figure 4. General overview of the systematic approach for analyzing communication networks in 
the early micrometastatic microenvironment
The cues, signals and responses are color coded. Adapted from (74).
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